Access to High Cost Medicines: An Overview
- 1 January 2018
- book chapter
- Published by Elsevier BV
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015Value in Health, 2018
- Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs FundAnnals of Oncology, 2017
- Improving Access to New Treatments with Value Based Pricing: An Indian PerspectivePharmacology, Toxicology and Biomedical Reports, 2015
- Pricing in the Market for Anticancer DrugsJournal of Economic Perspectives, 2015
- Despite High Costs, Specialty Drugs May Offer Value For Money Comparable To That Of Traditional DrugsHealth Affairs, 2014
- International Variability in the Reimbursement of Cancer Drugs by Publically Funded Drug ProgramsCurrent Oncology, 2012
- Less Than Ideal: How Oncologists Practice With Limited Drug AccessJournal of Oncology Practice, 2012
- Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?British Journal of Cancer, 2012
- Limits on Medicare's Ability to Control Rising Spending on Cancer DrugsThe New England Journal of Medicine, 2009
- Transferring the costs of expensive treatments from secondary to primary careBMJ, 1995